Moderna Sinks Another 8% Even as Lead Investigator Calls Melanoma Vaccine Data “Transformational”

Key TakeawaysModerna shares fell another 8% this morning. On Saturday it and its partner Merck presented full Phase 3 data showing their personalized melanoma vaccine cut the risk of recurrence or death by 42%.